Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSolly, E.L.en
dc.contributor.authorDimasi, C.G.en
dc.contributor.authorBursill, C.A.en
dc.contributor.authorPsaltis, P.J.en
dc.contributor.authorTan, J.T.M.en
dc.identifier.citationJournal of Clinical Medicine, 2019; 8(12):2199-1-2199-26en
dc.description.abstractAtherosclerotic cardiovascular disease remains the leading cause of morbidity and mortality worldwide. Atherosclerosis develops over several decades and is mediated by a complex interplay of cellular mechanisms that drive a chronic inflammatory milieu and cell-to-cell interactions between endothelial cells, smooth muscle cells and macrophages that promote plaque development and progression. While there has been significant therapeutic advancement, there remains a gap where novel therapeutic approaches can complement current therapies to provide a holistic approach for treating atherosclerosis to orchestrate the regulation of complex signalling networks across multiple cell types and different stages of disease progression. MicroRNAs (miRNAs) are emerging as important post-transcriptional regulators of a suite of molecular signalling pathways and pathophysiological cellular effects. Furthermore, circulating miRNAs have emerged as a new class of disease biomarkers to better inform clinical diagnosis and provide new avenues for personalised therapies. This review focusses on recent insights into the potential role of miRNAs both as therapeutic targets in the regulation of the most influential processes that govern atherosclerosis and as clinical biomarkers that may be reflective of disease severity, highlighting the potential theranostic (therapeutic and diagnostic) properties of miRNAs in the management of cardiovascular disease.en
dc.description.statementofresponsibilityEmma L. Solly, Catherine G. Dimasi, Christina A. Bursill, Peter J. Psaltis, and Joanne T.M. Tanen
dc.rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
dc.subjectInflammation; oxidative stress; angiogenesis; endothelial dysfunction; smooth muscle cells; foam cell formation; plaque stability; plaque rupture; vasa vasorumen
dc.titleMicroRNAs as therapeutic targets and clinical biomarkers in atherosclerosisen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidSolly, E.L. [0000-0001-9992-1181]en
dc.identifier.orcidBursill, C.A. [0000-0002-0682-8760]en
dc.identifier.orcidPsaltis, P.J. [0000-0003-0222-5468]en
dc.identifier.orcidTan, J.T.M. [0000-0003-1875-4882]en
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_123535.pdfPublished Version1.22 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.